RxDoctor Payments Data

Norman Bennett, MD

Cardiovascular Disease · Stuart, FLNPI 1093776411

Payments from drug & device makers

$751in general payments, 2019–2025

Across 36 payments — averaging $20.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$236
  • Abbott$72
  • Pfizer$69
  • Heartflow, Inc.$68
  • Biosense Webster, Inc.$65
  • AstraZeneca$37
  • plus $206 from 10 others

What the payments were for

  • Food & beverage$751100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$751 in reported general payments places this provider in the 20th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$1,258,853
Medicare patients
4,138
Services billed
16,382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban947$1,174,071
VyndamaxTafamidis26$632,277
XareltoRivaroxaban364$469,242
EntrestoSacubitril/Valsartan153$150,679
Repatha SureclickEvolocumab99$137,432
JardianceEmpagliflozin21$29,175
Praluent PenAlirocumab20$18,316
Metoprolol Succinate867$12,967
FarxigaDapagliflozin Propanediol15$12,131
Atorvastatin Calcium912$9,644
BrilintaTicagrelor11$9,272
Rosuvastatin Calcium542$8,128
Flecainide Acetate211$8,043
Labetalol Hcl274$7,277
Amlodipine Besylate909$6,799

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$69$1,806,348973 claims
Johnson & JohnsonXarelto$28$469,242364 claims
NovartisEntresto$236$150,679153 claims
AstraZenecaFarxiga, Brilinta$37$21,40326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Stuart

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →